Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a biopharmaceutical company focused on rare diseases, announced that its CEO, Axel Bolte, will present at the Jefferies Healthcare Conference on June 8, 2022, at 2:30 PM ET. The presentation will discuss the company’s advancements in developing therapies for abnormal mineralization diseases, particularly those related to ENPP1 and ABCC6 deficiencies. A replay of the presentation will be available on the Investor Relations section of Inozyme's website.

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference. The presentation will take place on Wednesday, June 8, 2022 at 2:30 PM ET.

A replay of the presentation can be accessed from the Investor Relations section of Inozyme’s website and will be available for a limited time following the events.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
857-330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
973-886-9150
matt.pera@smithsolve.com

FAQ

What is Inozyme Pharma's focus on abnormal mineralization diseases?

Inozyme Pharma develops therapies targeting diseases related to abnormal mineralization, particularly those linked to gene deficiencies in ENPP1 and ABCC6.

When will Axel Bolte present at the Jefferies Healthcare Conference?

Axel Bolte is scheduled to present on June 8, 2022, at 2:30 PM ET.

Where can I find the replay of Inozyme's presentation?

The replay of Inozyme's presentation will be accessible from the Investor Relations section of their website.

What is the ticker symbol for Inozyme Pharma?

The ticker symbol for Inozyme Pharma is INZY.

What clinical trials is Inozyme currently conducting?

Inozyme is conducting Phase 1/2 clinical trials for its therapy INZ-701 targeting ENPP1 and ABCC6 deficiencies.